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Abstract: Women persistently infected with human papillomavirus (HPV) type 16 are at high risk for development of 
cervical intraepithelial neoplasia grade 3 or cervical cancer (CIN3+). We aimed to identify biomarkers for progres-
sion to CIN3+ in women with persistent HPV16 infection. In this prospective study, 11,088 women aged 20-29 
years were enrolled during 1991-1993, and re-invited for a second visit two years later. Cervical cytology samples 
obtained at both visits were tested for HPV DNA by Hybrid Capture 2 (HC2), and HC2-positive samples were geno-
typed by INNO-LiPA. The cohort was followed for up to 19 years via a national pathology register. To identify markers 
for progression to CIN3+, we performed microarray analysis on RNA extracted from cervical swabs of 30 women 
with persistent HPV16-infection and 11 HPV-negative women. Six genes were selected and validated by quantita-
tive PCR. Three genes were subsequently validated within a different and large group of women from the same 
cohort. Secondly, Kaplan-Meier and Cox-regression analyses were used to investigate whether expression levels of 
those three genes predict progression to CIN3+. We found that high transcript levels of TMEM45A, SERPINB5 and 
p16INK4a at baseline were associated with increased risk of CIN3+ during follow-up. The hazard ratios of CIN3+ 
per 10-fold increase in baseline expression level were 1.6 (95% CI: 1.1-2.3) for TMEM45A, 1.6 (95% CI: 1.1-2.5) 
for p16INK4a, and 1.8 (95% CI: 1.2-2.7) for SERPINB5. In conclusion, high mRNA expression levels of TMEM45A, 
SERPINB5 and p16INK4a were associated with increased risk of CIN3+ in persistently HPV16-infected women.  
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Introduction
Of all high-risk HPV types, HPV16 has the great-
est carcinogenic potential [1, 2], and women 
with a persistent HPV16 infection are at high 
risk of subsequent cervical intraepithelial neo-
plasia grade 3 or cervical cancer (CIN3+) [1, 3, 
4]. Nevertheless, not all women with a persis-
tent HPV16 infection develop CIN3+, and little 
is known about the reasons why some women 
progress to CIN3+ while others do not. 
The identification of differentially expressed 
genes before progression of a persistent HPV- 
16 infection to CIN3+ might help to clarify the 
molecular mechanisms underlying progressi- 
on.
Previous studies have thus far identified the 
viral protein L1 [5], cellular markers such as 
transglutaminase enzyme type 2 [6], p16INK4a/
Ki-67 [7] and SERPINB5 [8, 9] as well as spe-
cific miRNAs including miR-375, miR-218 or 
miR-34a [10-12] as potential biomarkers for 
the progression to CIN3+. However, these stud-
ies were of cross-sectional design and com-
pared expression levels of low-grade versus 
high-grade cervical lesions. Only p16INK4a has 
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been the subject of prospective studies, and a 
high expression level of p16INK4a-protein was 
found to be associated with an increased risk 
of progression to high-grade CIN or cervical 
cancer. Its predictive value was determined for 
its protein levels by performing immunohisto-
chemistry staining of biopsy [13-17] or cytology 
samples [18].
In the present cohort study with up to 19 years 
of follow-up, we aimed at identifying differen-
tially expressed genes that mark the progres-
sion to CIN3+ in women with a persistent 
HPV16 infection at baseline as this is the most 
prevalent HR type infection.
Gene expression microarray analysis was used 
to identify a set of potential candidate markers 
for progression. Analysis of SERPINB5 and 
p16INK4a mRNA levels were included based 
on the potential predictive value of these two 
markers described in previous reports.
Material and methods
Study cohort
The present study is based on the Danish HPV 
cohort, which has previously been described in 
detail [1, 19]. Briefly, 11,088 Danish women 
aged 20-29 years from the general female pop-
ulation of Copenhagen were enrolled during 
1991-1993. Two years later, the women were 
re-invited for a second visit, and a total of 8,656 
women participated. At both visits, a Pap-sme- 
ar was taken, and endo-ectocervical cell mate-
rial was obtained for HPV testing. Cervical sam-
ples were placed in phosphate-buffered saline 
(with 0.05% methiolate), stored at -80°C, and 
tested by Hybrid Capture 2 (HC2) (Qiagen, 
Hilden, Germany). HPV-positive samples were 
genotyped by INNO-LiPA Genotyping (Innoge- 
netics, Ghent, Belgium) as previously described 
[1, 19].
The cohort was subsequently followed via the 
Danish national Pathology Data Bank [20], 
which enabled us to obtain normal and abnor-
mal cervical diagnoses of all participating wo- 
men. Abnormal cervical diagnoses were report-
ed either according to the dysplasia nomencla-
ture (atypia, mild dysplasia, moderate dyspla-
sia, severe dysplasia, carcinoma in situ, and 
cancer), the Bethesda nomenclature for cyto-
logical diagnoses, or the CIN nomenclature for 
histological diagnoses. In our analyses, histo-
logical diagnoses of severe dysplasia, carcino-
ma in situ (including adenocarcinoma in situ), 
CIN3 or cancer (including adenocarcinoma) 
were categorized as CIN3+. We defined base-
line as the date of the second study visit.
Consent and approval
Before entering the study, all participants were 
informed verbally and in writing about the study, 
and all participants signed a written informed 
consent. The study was approved by the nation-
al Scientific Ethics Committee and the national 
Data Protection Board.
RNA extraction
RNA was extracted from cervical swab samples 
obtained at the second study visit. Extraction 
was done using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany), and the RNA was stored at 
-80°C. RNA quality was determined using an 
Agilent Bioanalyzer 2100.
Microarray analysis
RNA amplification and hybridization to Affym- 
etrix Human Genome U133 Plus 2.0 arrays 
were performed at the Microarray Facility Tü- 
bingen following standard Affymetrix proce-
dures. The final data analysis was performed by 
Genedata AG, Basel, as follows: The quality co- 
ntrol of the data files from the Human Genome 
U133 Plus 2.0 arrays was performed using 
Refiner Array from Genedata AG. Expression va- 
lues for all probe sets were obtained by apply-
ing the GeneChip Robust Multi-array Average 
condensing method (GC-RMA) [21]. No microar-
ray showed local areas of significantly increased 
or decreased intensities, and no systematic 
biases (defects, gradient, distortion, backgrou- 
nd) were found. All transcriptional profiles have 
been submitted to the GEO database at NCBI 
(Accession number: GSE75132).
Quantitative real-time PCR (qPCR)
Primer pairs for the respective biomarker genes 
were designed using PRIMER3 plus software 
[22] (Table 1). RNA was reverse transcribed 
using the Reverse Transcription kit from Qiagen 
(Hilden, Germany). RNA concentration was 
determined by NanoDrop and absolute RNA 
amount used for cDNA synthesis ranged from 
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10 pg to 1 µg cDNA. 5 µl sample cDNA was 
subjected to qPCR (Roche Light Cycler 480, 
Roche Diagnostics) using 1x Light Cycler 480 
SYBR green I Master Mix (Roche Diagnostics), 
0.3 µM primer and PCR grade H2O. Specificity 
was verified by melting curve analysis. The tr- 
anscript levels of each gene, calculated using 
standard curves, were normalized to PGK1 tr- 
anscript levels to calculate relative mRNA am- 
ounts.
Statistical analysis
The logarithmized gene expression values from 
the microarray analyses were normalized by 
locally weighted scatterplot smoothing (LOW- 
ESS) [23] and by shifting the medians of each 
experiment to a value of 10,000. In order to 
eliminate possible batch effects, expression 
values were divided by the medians of the cor-
responding HPV-negative control group. Signi- 
ficantly deregulated genes were selected using 
t-tests for independent samples and Wilcoxon 
rank sum tests. Statistics were computed ba- 
sed on the logarithmized and normalized exp- 
ression values. The p-value, a permutation q- 
value (100 repeats) and the Benjamini-Hoch- 
berg q-value (false discovery rate, FDR) [24] 
were derived. In addition, we calculated the fold 
change of the means of the groups.
When analyzing whether the identified genes 
could predict progression to CIN3+ among per-
sistently HPV16-infected women, we estimated 
the cumulative incidence of CIN3+ during fol-
gorization at the median and for 10-fold 
increase (continuous scale). The analysis was 
adjusted for age at baseline. In both the 
Kaplan-Meier and the Cox regression analyses, 
time to event was measured from baseline (i.e. 
date of the second study visit) to date of CIN3+-
diagnosis. Repeating the Cox regression using 
the mid-point between date of diagnosis and 
date of last examination without CIN3+ did not 
alter our conclusions.
Results
Figure 1 illustrates the design of the present 
analysis. First, we selected those women from 
the original cohort who had normal cervical 
cytology at baseline and no abnormal smears 
within one year before baseline (n=7,679). Of 
these, we identified 82 women with a persis-
tent HPV16 infection at the second study visit 
and at least one cervical examination in the 
Pathology Databank during follow-up. Persistent 
HPV16 infection was defined as testing positive 
for HPV16 DNA by the INNO-LiPA test at both 
study visits 2 years apart. The median age of 
the 82 women was 26 years (range 22-32 
years). As a control group for the discovery set 
for the gene expression analysis, we selected 
an age-matched sample of 30 women who 
were negative for HPV DNA by HC2 at both 
study visits and who did not develop cervical 
abnormalities during follow-up (henceforth 
referred to as HPV-negative women). The pur-
pose of the control group was to validate the 
analysis undertaken by identifying genes differ-
Table 1. Oligonucleotide primers for quantitative real-time PCR
Gene Symbol ID Primer Sequence
TMEM45A 219410_at Forward AGTTGGATGCCCACACTATG
Reverse AGTAGCAAGCCCAGTAACCTTG
TNFAIP6 206025_s_at Forward TTGAAGATGACCCAGGTTGC
Reverse CATCTGGAAGCTCATCTCCAC
CD44 204490_s_at Forward AAGGTGGAGCAAACACAACC
Reverse GCTTTTTCTTCTGCCCACAC
CCRL2 211434_s_at Forward GGCGCGGAAATTTGTCTAAG
Reverse CCAGGGTTTGGAGTTTGATG
SERPINB5 204855_at Forward GTTGCCGGTTCATGGATTAC 
Reverse GCATGTCAAGGAAGAGATGG 
PGK 1 Forward CTGTGGGGGTATTTGAATGG
Reverse CTTCCAGGAGCTCCAAACTG
p16INK4a Qiagen QuantiTect Primer Assay
(#QT00089964) for CDKN2A
low-up using the Kaplan-Meier 
method. For this analysis, gene 
expression values were dichot-
omized at the median. Further- 
more, we used Cox proportional 
hazard models to estimate the 
hazard ratio (HR) with corre-
sponding 95% confidence inter-
vals (CIs) of progression to 
CIN3+ during follow-up accord-
ing to gene expression levels 
at baseline. In the Cox models, 
we used continuous log-trans-
formed gene expression values 
as well as categorical gene 
expression values (dichoto-
mized at the median) as the 
independent variable. Hazard 
ratios are given for both, cate-
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Figure 1. Overview of study design. CIN, Cervical intraepithelial neoplasia; qPCR, quantitative real-time PCR; HPV, Human papillomavirus.
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Gene symbol Chromosome Gene description Gene ontology T-test (p-value) Ratio of means1
TMEM45A 3q12.2 Transmembrane protein 45A Integral to membrane < 0.0001 3.63
TNFAIP6 2q23.2 Tumor necrosis factor, alpha-induced protein 6 Inflammatory response, cell adhesion, signal transduction, cell-cell signa-
ling
< 0.0001 0.05
CD44 11p13 CD44 antigen (homing function and Indian blood group system) Regulation of cell growth, inflammatory response, cell adhesion, cell migra-
tion
< 0.0001 0.14
CCRL2 3p21 Chemokine (C-C motif) receptor-like 2 Chemotaxis, signal transduction, receptor activity < 0.00001 0.04
p16INK4a2 9p21 Cyclin-dependent kinase inhibitor 2A Cell cycle checkpoint, regulation of cyclin-dependent protein kinase activity, 
G1/S transition of mitotic cell cycle, DNA fragmentation involved in apopto-
sis, transcription
0.5193 0.93
SERPINB52 18q21.3 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 Cell motion, serine-type endopeptidase inhibitor activity, protein binding 0.0144 2.69
1Ratio of means was computed as „mean expression value in persistently HPV16-infected women“ / „mean expression value in HPV-negative women“ 2Included in analysis based on à priori hypotheses.
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Figure 2. Validation of microarray results by quantitative PCR. (A) on a subset of samples previously included in microarrays and (B) on independent samples not 
previously included in microarrays. Log-transformed (log10) mRNA levels in 24 and 41 women with persistent HPV16 infection, compared to 5 and 10 HPV-negative 
women, respectively. P-values refer to T-test for independent samples using logarithmic transformed gene expression values. Solid line indicates mean of log-
transformed transcript levels; *Normalized to PGK1 transcript levels; HPV, Human papillomavirus.
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entially expressed in women with persistent 
HPV16 infection compared with HPV-negative 
women, as a proof of principle as the samples 
were collected under suboptimal conditions for 
the later RNA analysis. A total of 20 women (11 
women with persistent HPV16 infection and 9 
HPV-negative women) were excluded from all 
analyses due to insufficient RNA, missing/
questionable control gene statistics or low 
number of transcripts (< 10%) present on mic- 
roarrays. Thus, the final study population 
included 71 women with persistent HPV16 
infection, and 21 women who were HPV-
negative at baseline (Figure 1).
Microarray analysis
Based on RNA quality analysis, samples with 
similar RNA integrity numbers were selected for 
microarray experiments. The microarray analy-
sis included a total of 41 samples (30 of the 71 
samples from women with persistent HPV16 
infection, and 11 of the 21 samples from HPV-
negative women; Figure 1).
T-test analysis of the microarray data resulted 
in 3,177 altered transcript levels at p-values 
< 0.01, an FDR of 0.18, and a permutation 
q-value of 0.17. A total of 1,519 genes showed 
fold changes of > 2 or < 0.5. Of these, 1,090 
were down-regulated, and 429 were up-regulat-
ed in persistently HPV16-infected women com-
pared with HPV-negative women. The Wilcoxon 
rank sum test confirmed the total number of 
deregulated genes, with 1,430 genes showing 
fold changes of > 2 or < 0.5 (975 down-regulat-
ed and 455 up-regulated genes). The overlap 
between the 3,177 transcripts from the t-tests 
and the 3,177 transcripts from the Wilcoxon 
tests counted 2,596 transcripts, and the over-
Figure 3. Cumulative incidence of CIN3+ during 
follow-up in 65 women with persistent HPV16 in-
fection at baseline, according to expression level 
of TMEM45A (A), p16INK4a (B), and SERPINB5 (C) 
at baseline. CIN3+, Cervical intraepithelial neopla-
sia grade 3 or worse; HPV, Human papillomavirus. 
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lap between the 1,519 and 1,430 transcripts 
with fold changes of > 2 or < 0.5 comprised 
1,366 transcripts.
From this pool of significantly deregulated 
genes, we selected one up-regulated gene 
(TMEM45A) and three down-regulated genes 
(TNFAIP6, CD44 and CCRL2) for validation by 
qPCR. The selection was performed by degree 
of statistical significance (all p-values < 0.0001) 
and the extent of deregulation (ratio of means 
ranging from 0.04-3.63) (Table 2). Moreover, 
p16INK4a and SERPINB5 were selected for fur-
ther analyses based on previous findings [8, 9, 
13, 18]. A description of the ontology of the 
selected genes is provided in Table 2.
Validation by qPCR
In order to confirm the differential expression 
of the selected genes, we performed two vali-
dation assays using qPCR. The first qPCR vali-
dation was performed on the non-amplified 
original RNA samples previously included in the 
microarray analysis.
Due to insufficient material, only 29 samples 
(n=24 persistently HPV16-infected women, 
n=5 HPV-negative women) could be used for 
this analysis (Figure 1). Figure 2A presents the 
results of the first qPCR validation. This valida-
tion confirmed the results of the microarray 
data, showing that the expression of TMEM45A 
was increased in persistently HPV16-infected 
women compared with HPV-negative women 
(p=0.001), while the expression of TNFAIP6, 
CD44 and CCRL2 was reduced (p=0.026, 
p=0.030 and p=0.026, respectively). Fur- 
thermore, the analysis showed that p16INK4a 
and SERPINB5 were overexpressed in women 
with a persistent HPV16 infection compared 
with HPV-negative women (p=0.043 and p 
< 0.001, respectively). 
The results of the second qPCR validation was 
performed on a large group of 51 independent 
samples not previously included in the microar-
ray analysis, comprising 41 women with persis-
tent HPV16 infection and 10 HPV-negative 
women (Figure 1). Due to limited RNA amounts, 
this validation was performed only for the tran-
scripts of the three most promising genes, 
including TMEM45A, p16INK4a and SERPINB5. 
TMEM45A and SERPINB5 were selected bec- 
ause they showed the most significant differ-
ence between HPV-negative and persistently 
HPV16-infected women in the first validation 
analysis (p=0.001 and p < 0.001, respectively, 
Figure 2A). P16INK4a was selected due to a 
previous report demonstrating that overexpres-
sion of this marker might be predictive for the 
risk of incident high-grade cervical lesions in 
HPV-positive women [18]. Figure 2B presents 
the results of the second qPCR validation. This 
analysis confirmed significantly higher mRNA 
transcript levels for TMEM45A (p=0.032), p16- 
INK4a (p=0.005) and SERPINB5 (p < 0.001) in 
women with persistent HPV16 infection com-
pared with HPV-negative women (Figure 2B). 
Table 3. Hazard ratios of CIN3+ during up to 19 years of follow-up in 65 women with persistent 
HPV16 infection at baseline, according to expression level of TMEM45A, p16INK4a and SERPINB5 as 
measured by quantitative real-time PCR at baseline
Main analysis Sensitivity analysis using midpoint of time interval
 Expression level
CIN3+ Age-adjusted 
HR of CIN3+ (95% CI)
Age-adjusted 
HR of CIN3+ (95% CI)N n (%)
TMEM45A < Median 32 11 (34.4) 1.0 (ref) 1.0 (ref)
≥ Median 33 20 (60.6) 3.1 (1.4-6.7) 3.6 (1.7-7.9)
Continuous (per 10-fold increase) 65 31 (47.7) 1.6 (1.1-2.3) 1.2 (1.1-1.3)
p16INK4a* < Median 30 13 (43.3) 1.0 (ref) 1.0 (ref)
≥ Median 30 18 (60.0) 1.8 (0.9-3.7) 2.2 (1.0-4.5)
Continuous (per 10-fold increase) 60 31 (51.7) 1.6 (1.1-2.5) 1.2 (1.1-1.4)
SERPINB5 < Median 33 10 (30.3) 1.0 (ref) 1.0 (ref)
≥ Median 32 21 (65.6) 4.2 (1.9-9.3) 4.8 (2.2-10.7)
Continuous (per 10-fold increase) 65 31 (47.7) 1.8 (1.2-2.7) 1.2 (1.1-1.3)
*Five women with missing p16INK4a values were excluded. CI, Confidence interval; CIN3+, Cervical intraepithelial neoplasia grade 3 or worse; 
HPV, Human papillomavirus; HR, Hazard ratio; (ref), reference group.
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Prediction of progression to CIN3+
Following the validation analyses, we examined 
whether the transcript levels of the three 
selected genes were predictive for progression 
to CIN3+ during follow-up in women with persis-
tent HPV16 infection at baseline. In this analy-
sis, we included women with persistent HPV16 
infection at baseline from the first (n=24) and 
the second (n=41) validation analyses, result-
ing in a total of 65 women for the progression 
analysis (Figure 1). Of these 65 persistently 
HPV-16 infected women, 29 women developed 
CIN3, and 2 developed cancer during up to 
19.3 years of follow-up, resulting in 31 (53.4%) 
cases of CIN3+.
Figure 3A-C show the cumulative incidence of 
CIN3+ during follow-up according to baseline 
expression levels of TMEM45A, p16INK4a and 
SERPINB5. For all three genes, high (≥ median) 
transcript levels at baseline were associated 
with a higher cumulative incidence of CIN3+ 
during follow-up than low (< median) transcript 
levels. Furthermore, the Kaplan-Meier curves 
indicated that TMEM45A or SERPINB5 tran-
script levels allowed a more pronounced sepa-
ration of progressors versus non-progressors 
than p16INK4a transcript levels.
Finally, Table 3 shows the age-adjusted hazard 
ratios (HRs) of CIN3+ in women with persistent 
HPV16 infection at baseline, according to base-
line gene expression levels. For TMEM45A and 
SERPINB5, baseline transcript levels above ver-
sus below the median were significantly associ-
ated with higher CIN3+ risk during follow-up 
(TMEM45A: HR=3.1, 95% CI: 1.4-6.7; SERP- 
INB5: HR=4.2, 95% CI: 1.9-9.3). The same pat-
tern, although not statistically significant, was 
observed for p16INK4a (HR=1.8, 95% CI: 0.9-
3.7). Assuming a log-linear association between 
gene expression levels and the hazard of 
CIN3+, all three genes showed a 60-80% 
increased hazard of CIN3+ per 10-fold increase 
in the expression level (TMEM45A: HR=1.6, 
95% CI: 1.1-2.3; SERPINB5: HR=1.8, 95% CI: 
1.2-2.7; p16INK4a: HR=1.6, 95% CI: 1.1-2.5).
Discussion
In the present study, we employed microarray 
analysis and qPCR to cervical cytology samples 
of a population-based cohort which has been 
followed for up to 19 years with virtually no loss 
to follow-up. We found that in women with nor-
mal cytology and persistent HPV16 infection at 
baseline, increased mRNA expression of 
TMEM45A, SERPINB5 and p16INK4a was 
associated with an increased risk of progres-
sion to CIN3+ during follow-up. 
The TMEM45A (transmembrane protein 45A; 
also known as DERP7, DNAPTP4 or FLJ10134) 
gene belongs to the family of uncharacterized 
predicted transmembrane proteins and con-
tains the Pfam domain DUF716 (domain of 
unknown function) which is associated with 
viral infection in plants (InterPro IPR006904). 
The function of TMEM45A remains unknown. It 
has been shown that TMEM45A is a hypoxia 
inducible gene [25, 26] with anti-apoptotic 
functions under genotoxic stress [27], and the 
expression of TMEM45A in cancer cells sup-
pressed progression of ductual carcinoma into 
invasive breast cancer [28]. TMEM45A is highly 
expressed in human keratinocytes [29], and it 
was reported to be associated with keratino-
cyte differentiation [30, 31]. Up-regulation of 
TMEM45A expression was found in psoriasis 
and actinic keratosis [31, 32]. TMEM45A has 
previously been described as a marker for sur-
vival of breast cancer patients. Patients with 
high expression within the tumor tissue had a 
significantly lower relapse-free survival than 
those with a low expression [27]. Almost 90% 
of all cervical cancers reveal a gain of chromo-
some 3q, which carries the TMEM45A gene 
[33]. It therefore seems plausible that early 
overexpression of TMEM45A might constitute a 
marker for progression to high-grade cervical 
lesions in high-risk HPV-infected women.
In contrast SERPINB5 or Maspin (mammary 
serine protease inhibitor) has previously been 
reported to be differentially expressed in cer-
tain types of cancer. A reduced expression was 
found in prostate cancer [8], breast cancer [34] 
and gastric carcinoma [35], which supports a 
tumor suppressor role of SERPINB5 in tumor 
progression. However, increased expression of 
SERPINB5 was observed in ovarian cancer 
[36], breast cancer [37], gastric adenocarcino-
ma [38], colorectal [39, 40], pancreatic [41] 
and gallbladder cancer [42], suggesting that 
overexpression is involved in tumor progres-
sion in these tissues. Previously published data 
also showed that SERPINB5 might play a role in 
disease progression from in situ to invasive cer-
TMEM45A, SERPINB5 and p16INK4A mRNA levels predict CIN3+
1533 Am J Cancer Res 2016;6(7):1524-1536
vical cancer [9], and Liu et al. reported that 
nuclear localization of SERPINB5 might be a 
marker for prognosis of cervical cancer patients 
[8]. This is consistent with our results, showing 
that a higher expression of SERPINB5 in persis-
tently HPV16-infected women with normal 
cytology has the potential to predict progres-
sion to CIN3+.
In contrast to TMEM45A and SERPINB5, immu-
nohistological staining for p16INK4a expres-
sion is already being used as a tool for manag-
ing patients with atypical squamous cells of 
undetermined significance (ASC-US) or low-
grade squamous intraepithelial lesion (LSIL) 
cytology results and for triaging HPV-positive 
women [43]. The p16INK4a protein is a cyclin-
dependent kinase (CDK) inhibitor, which is 
induced by cellular stress including the pres-
ence of the papillomavirus oncogene E7. 
Because of an epigenetic derepression medi-
ated by E7, HPV-associated tumors express 
high levels of p16INK4a, which justifies its use 
as a marker for neoplastic lesions [44]. A recent 
prospective analysis investigated the relation 
between p16INK4a protein positivity in cytolo-
gy specimens and the subsequent risk of CIN2+ 
during 3 years of follow-up [18]. In accordance 
with our results, this study demonstrates that 
p16INK4a overexpression is a predictive mark-
er for the development of CIN2+ or worse in 
women positive for HPV irrespective of the 
type.
A main strength of our study is the initial use of 
microarray analysis as an unbiased approach 
to identify a set of cellular genes deregulated in 
women with persistent HPV16 infection. This 
allowed us to combine a genome-wide search 
for new potential progression markers with pre-
viously published data on potential markers. 
Furthermore, the follow-up via the nationwide 
pathology register enabled an extended follow-
up period with virtually no loss. Lastly, because 
HPV-status was measured at two time points, 
we were able to identify women with a persis-
tent HPV16-infection (HPV16-positive at both 
visits). Therefore, we could focus our analysis 
on those women who are at highest risk for the 
development of CIN3+ [1, 45].
A limitation of our study is that although the 
Danish HPV cohort study included more than 
11,000 women, there were relatively few 
CIN3+-cases in the study population for the 
present analysis (n=31). Therefore, we were 
unable to evaluate progression to CIN3 and 
cervical cancer separately. Furthermore, cervi-
cal swabs were stored in a buffer not suitable 
for RNA storage, which led to a certain degree 
of RNA degradation. Due to limited RNA 
amounts, we could not include all of the poten-
tial genetic markers identified by microarrays in 
the analysis of the risk for progression to CIN3+. 
In conclusion, we found that high expression 
levels of TMEM45A, SERPINB5 and p16INK4a 
mRNA in persistently HPV16-infected women 
with normal cervical cytology increases the risk 
of future CIN3+. Further investigation is needed 
to clarify the roles of TMEM45A and SERPINB5 
in disease development, which might ultimately 
help to assess the potential of those markers 
for risk stratification as well as to a better 
understanding of the biological processes 
causing progression to CIN3+ in some, but not 
all persistent HPV16 infections.
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